Mouse Study Shows Possible Benefits of Targeting Immune Messenger IL-17A in MS
February 7, 2020
The immune messenger protein IL-17A has long been known to be a major player in the immune attacks that underlie MS. Researchers at Trinity College Dublin are now reporting that – in studies in mice with MS-like disease -- IL-17A appears to act by priming other immune system components, and not by triggering inflammation itself. Eliminating IL-17A from mice or treating them with inhibitors of IL-17A enabled the mice to resist getting MS-like disease. Antibodies targeting this immune protein are in development, and one has been approved to treat another immune-mediated disease – plaque psoriasis. These studies can serve to inform similar future efforts in MS.
Read more from Trinity College
Read a summary of the paper in Immunity
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.